Comparison of long‐term outcomes between imatinib and dasatinib prophylaxis after allogeneic stem cell transplantation in patients with Philadelphia‐positive acute lymphoblastic leukemia: A multicenter retrospective study

Documenti analoghi

• Higher risk of platelet engraftment failure and chronic graft‐versus‐host disease after allogeneic haematopoietic stem cell transplantation following chimeric antigen receptor T‐cell therapy compared to chemotherapy: A propensity score‐matched analysis
  di: Luxin Yang, et al.
  Pubblicazione: (2025)
• Outcomes following allogeneic hematopoietic cell transplantation relapse in Philadelphia chromosome‐positive acute lymphoblastic leukemia
  di: Tamer Othman, et al.
  Pubblicazione: (2024)
• Graft CD8 T‐cell‐based risk system predicts survival in antithymocyte globulin‐based myeloablative haploidentical peripheral blood stem cell transplantation
  di: Panpan Zhu, et al.
  Pubblicazione: (2024)
• Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A multi‐institutional study
  di: Talha Badar, et al.
  Pubblicazione: (2024)
• Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome‐positive acute lymphoblastic leukemia
  di: Tamer Othman, et al.
  Pubblicazione: (2024)